Inception | $50,000,000 | (Nov 7, 2025)
SiteLabs | $2,000,000 | (Nov 7, 2025)
DealMaker | $20,000,000 | (Nov 7, 2025)
Certified by Founder
Lodge
Wugen
start up
United States
- St Louis, Missouri
- 17/03/2022
- Unknown
- $200,000,000
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.
Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.
- Industry Biotechnology
- Website https://www.wugen.com/
- LinkedIn https://www.linkedin.com/company/wugen/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
Flint(US) | $15,000,000 | (Nov 7, 2025)
Subtle Computing | $6,000,000 | (Nov 7, 2025)
IndustrialMind.ai | $1,200,000 | (Nov 7, 2025)
Fintary | $10,000,000 | (Nov 7, 2025)
Graymatter Labs | $1,300,000 | (Nov 7, 2025)
Avallon AI (YC X25) | $4,600,000 | (Nov 7, 2025)
Kaizen Labs | $12,000,000 | (Nov 7, 2025)
Giga | $61,000,000 | (Nov 7, 2025)
Reevo | $80,000,000 | (Nov 7, 2025)